PDCD1 and gastric cancer: The anti-PD-1 agent nivolumab demonstrated survival benefits in refractory unresectable advanced or recurrent GC/GEJC, irrespective of PD-L1 expression status, leading to regulatory approval in Japan (Kang et al., 2017).